Enhanced Oral Bioavailability of &beta;-Caryophyllene in Healthy Subjects Using the VESIsorb&reg; Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS)

β-Caryophyllene (BCP), a common constituent of many spice and food plants, is gaining increased attention due to recent research identifying numerous potential health benefits. Due to limited oral bioavailability observed in preclinical models, the described benefits of BCP may be maximized by using a suitable delivery system. Additionally, human pharmacokinetics (PK) remain unknown. This study evaluates the relative oral bioavailability of BCP formulated in a self-emulsifying drug delivery system (SEDDS) based on VESIsorb^® formulation technology (BCP-SEDDS) compared to BCP neat oil. Hence, a randomized, double-blind, cross-over design, single oral dose study (100 mg BCP) in 24 healthy subjects (12 men/12 women) was performed under fasting conditions. Pharmacokinetic parameters were analyzed from individual concentration-time curves. The data show that BCP-SEDDS resulted in a 2.2/2.0-fold increase in AUC_0–12h/AUC_0–24h and a 3.6-fold increase in C_max compared to BCP neat oil. Moreover, BCP was absorbed faster from BCP-SEDDS (T_max: 1.43 h) compared to BCP neat oil (T_max: 3.07 h). Gender analysis revealed that there is no significant difference between men and women for both the investigated formulations and all investigated PK endpoints. In conclusion, BCP-SEDDS offers a well-tolerated and effective oral delivery system to significantly enhance the oral bioavailability of BCP in humans. View Full-Text

Keywords: beta-caryophyllene (BCP); bioavailability; hemp; Cannabis sativa L.; human; oral drug delivery system; pharmacokinetic; SEDDS; VESIsorb^® formulation technology; endocannabinoid system; nutraceuticals

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 236 KiB)

Share and Cite

MDPI and ACS Style

Mödinger, Y.; Knaub, K.; Dharsono, T.; Wacker, R.; Meyrat, R.; Land, M.H.; Petraglia, A.L.; Schön, C. Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb^® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS). Molecules 2022, 27, 2860. https://doi.org/10.3390/molecules27092860

AMA Style

Mödinger Y, Knaub K, Dharsono T, Wacker R, Meyrat R, Land MH, Petraglia AL, Schön C. Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb^® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS). Molecules. 2022; 27(9):2860. https://doi.org/10.3390/molecules27092860

Chicago/Turabian Style

Mödinger, Yvonne, Katharina Knaub, Tanita Dharsono, Roland Wacker, Remo Meyrat, M. Hunter Land, Anthony L. Petraglia, and Christiane Schön. 2022. "Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb^® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS)" Molecules 27, no. 9: 2860. https://doi.org/10.3390/molecules27092860

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Enhanced Oral Bioavailability of β-Caryophyllene in Healthy Subjects Using the VESIsorb^® Formulation Technology, a Novel Self-Emulsifying Drug Delivery System (SEDDS)

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI